Caribou Biosciences (CRBU) said Sunday it initiated the phase 1 trial evaluating its experimental therapy, CB-010, in patients with lupus nephritis and extrarenal lupus.
Additionally, the company said it expects to report data from a study of CB-010 to treat certain large B cell lymphoma patients in the first half of 2025.
Pending confirmation of its human leukocyte antigen matching strategy, Caribou said it expects to launch a phase 3 trial for CB-010 in H2 2025.
Meanwhile, the company also expects to present dose escalation data from its cancer drug CB-011 in relapsed or refractory multiple myeloma in H1 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。